Loading
PDBj
MenuPDBj@FacebookPDBj@TwitterPDBj@YouTubewwPDB FoundationwwPDB
RCSB PDBPDBeBMRBAdv. SearchSearch help

7SXF

BIO-2895 (BRD0705) bound GSK3alpha-axin complex

Summary for 7SXF
Entry DOI10.2210/pdb7sxf/pdb
DescriptorGlycogen synthase kinase-3 alpha, Axin peptide, (4~{S})-4-ethyl-7,7-dimethyl-4-phenyl-2,6,8,9-tetrahydropyrazolo[3,4-b]quinolin-5-one, ... (5 entities in total)
Functional Keywordskinase, hydrolase
Biological sourceHomo sapiens (Human)
More
Total number of polymer chains2
Total formula weight41663.10
Authors
Chodaparambil, J.V. (deposition date: 2021-11-23, release date: 2023-06-14, Last modification date: 2024-11-06)
Primary citationAmaral, B.,Capacci, A.,Anderson, T.,Tezer, C.,Bajrami, B.,Lulla, M.,Lucas, B.,Chodaparambil, J.V.,Marcotte, D.,Kumar, P.R.,Murugan, P.,Spilker, K.,Cullivan, M.,Wang, T.,Peterson, A.C.,Enyedy, I.,Ma, B.,Chen, T.,Yousaf, Z.,Calhoun, M.,Golonzhka, O.,Dillon, G.M.,Koirala, S.
Elucidation of the GSK3 alpha Structure Informs the Design of Novel, Paralog-Selective Inhibitors.
Acs Chem Neurosci, 14:1080-1094, 2023
Cited by
PubMed Abstract: Glycogen synthase kinase 3 (GSK3) remains a therapeutic target of interest for diverse clinical indications. However, one hurdle in the development of small molecule GSK3 inhibitors has been safety concerns related to pan-inhibition of both GSK3 paralogs, leading to activation of the Wnt/β-catenin pathway and potential for aberrant cell proliferation. Development of GSK3α or GSK3β paralog-selective inhibitors that could offer an improved safety profile has been reported but further advancement has been hampered by the lack of structural information for GSK3α. Here we report for the first time the crystal structure for GSK3α, both in apo form and bound to a paralog-selective inhibitor. Taking advantage of this new structural information, we describe the design and in vitro testing of novel compounds with up to ∼37-fold selectivity for GSK3α over GSK3β with favorable drug-like properties. Furthermore, using chemoproteomics, we confirm that acute inhibition of GSK3α can lower tau phosphorylation at disease-relevant sites in vivo, with a high degree of selectivity over GSK3β and other kinases. Altogether, our studies advance prior efforts to develop GSK3 inhibitors by describing GSK3α structure and novel GSK3α inhibitors with improved selectivity, potency, and activity in disease-relevant systems.
PubMed: 36812145
DOI: 10.1021/acschemneuro.2c00476
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (1.94 Å)
Structure validation

227111

PDB entries from 2024-11-06

PDB statisticsPDBj update infoContact PDBjnumon